In summary, our findings argue against a role for PPIs as potential treatment for preeclampsia, since daily administration of this drug was unable to improve the maternal circulating profile of sFlt-1, PlGF, and ET-1 in women with established preeclampsia. The gene discussed is PGF; the disease is preeclampsia.